Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 10/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26849718 | 0.87 | HTR6 (0.44) | KMT2AMEN1ALDH1A1MAPTTSHR | |
| SCHEMBL24298714 | 0.86 | HDAC3 (0.42) | KMT2AMEN1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL26845771 | 0.85 | TSHR (0.40) | KMT2AMEN1ALDH1A1MAPTTSHR | |
| SCHEMBL26837763 | 0.84 | CASP3 (0.42) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL26854979 | 0.84 | CA1 (0.48) | KMT2AMEN1FBP1ALDH1A1LMNA | |
| SCHEMBL26869358 | 0.83 | LOX (0.41) | KMT2AMEN1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL26854994 | 0.81 | MEN1 (0.54) | KMT2AMEN1KDM1AALDH1A1TSHR | |
| SCHEMBL29567131 | 0.81 | PIK3CG (0.38) | KMT2AMEN1ALDH1A1MAPTTSHR | |
| SCHEMBL26651235 | 0.81 | PIK3CG (0.38) | KMT2AMEN1ALDH1A1MAPTTSHR | |
| SCHEMBL26849603 | 0.79 | MAP4K4 (0.42) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | KMT2A 4644/4885MEN1 4643/4885KDM1A 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.